DK1581535T5 - Pyrrolopyridazinderivater - Google Patents

Pyrrolopyridazinderivater

Info

Publication number
DK1581535T5
DK1581535T5 DK03789642T DK03789642T DK1581535T5 DK 1581535 T5 DK1581535 T5 DK 1581535T5 DK 03789642 T DK03789642 T DK 03789642T DK 03789642 T DK03789642 T DK 03789642T DK 1581535 T5 DK1581535 T5 DK 1581535T5
Authority
DK
Denmark
Prior art keywords
pyrrolopyridazine
Prior art date
Application number
DK03789642T
Other languages
Danish (da)
English (en)
Other versions
DK1581535T3 (da
Inventor
Yoshito Abe
Makoto Inoue
T Mizutani
Kozo Sawada
Kazuhiko Ohne
M Okumura
Yuki Sawada
K Imamura
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2003900189A external-priority patent/AU2003900189A0/en
Priority claimed from AU2003903628A external-priority patent/AU2003903628A0/en
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Application granted granted Critical
Publication of DK1581535T3 publication Critical patent/DK1581535T3/da
Publication of DK1581535T5 publication Critical patent/DK1581535T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK03789642T 2003-01-09 2003-12-26 Pyrrolopyridazinderivater DK1581535T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2003900189A AU2003900189A0 (en) 2003-01-09 2003-01-09 Heterocyclic derivatives
AU2003903628A AU2003903628A0 (en) 2003-07-14 2003-07-14 Pyrrolopyridazine derivatives
PCT/JP2003/017091 WO2004063197A1 (fr) 2003-01-09 2003-12-26 Derives de pyrrolopyridazine

Publications (2)

Publication Number Publication Date
DK1581535T3 DK1581535T3 (da) 2008-02-11
DK1581535T5 true DK1581535T5 (da) 2009-12-21

Family

ID=32714072

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03789642T DK1581535T5 (da) 2003-01-09 2003-12-26 Pyrrolopyridazinderivater

Country Status (22)

Country Link
US (2) US7153854B2 (fr)
EP (1) EP1581535B3 (fr)
JP (1) JP4671104B2 (fr)
KR (1) KR101026819B1 (fr)
AR (1) AR042833A1 (fr)
AT (1) ATE376549T1 (fr)
BR (1) BR0317358A (fr)
CA (1) CA2513081C (fr)
CY (1) CY1107084T1 (fr)
DE (1) DE60317102T3 (fr)
DK (1) DK1581535T5 (fr)
ES (1) ES2291729T7 (fr)
HK (1) HK1088900A1 (fr)
IL (1) IL169500A0 (fr)
MX (1) MXPA05007462A (fr)
NO (1) NO20053748L (fr)
NZ (1) NZ541232A (fr)
PL (1) PL378245A1 (fr)
PT (1) PT1581535E (fr)
RU (1) RU2328499C2 (fr)
TW (1) TWI332004B (fr)
WO (1) WO2004063197A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1581535B3 (fr) 2003-01-09 2009-09-02 Astellas Pharma Inc. Derives de pyrrolopyridazine
US7030112B2 (en) * 2003-03-25 2006-04-18 Bristol-Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
US7459451B2 (en) * 2004-07-05 2008-12-02 Astellas Pharma Inc. Pyrazolopyridine derivatives
WO2006004191A1 (fr) * 2004-07-05 2006-01-12 Astellas Pharma Inc. Derivés de pyrrolopyridazine qui inhibent la pde iv et le tnf alpha
GB0422057D0 (en) * 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
AU2007315234A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
JP2009114123A (ja) * 2007-11-06 2009-05-28 Astellas Pharma Inc ２−アシル−１−アミノピロール化合物の新規製造法
EP2222639A1 (fr) 2007-11-21 2010-09-01 Decode Genetics EHF Inhibiteurs de biaryle pde4 pour le traitement de troubles pulmonaires et cardiovasculaires
MX2010007604A (es) 2008-01-11 2010-08-02 Novartis Ag Pirimidinas como inhibidores de cinasa.
JPWO2009154230A1 (ja) * 2008-06-17 2011-12-01 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
CA2738429C (fr) 2008-09-26 2016-10-25 Intellikine, Inc. Inhibiteurs heterocycliques de kinases
WO2010059836A1 (fr) * 2008-11-20 2010-05-27 Decode Genetics Ehf Composés bicycliques substitués à pont aza pour maladie cardiovasculaire et du système nerveux central
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
ES2865026T3 (es) * 2010-04-23 2021-10-14 Steam Tech Llc Sistema de limpiaparabrisas de superficie
US20130071415A1 (en) * 2010-05-28 2013-03-21 Biocryst Pharmaceuticals, Inc. Heterocyclic Compounds as Janus Kinase Inhibitors
CN103097383B (zh) 2010-09-07 2015-09-16 安斯泰来制药株式会社 吡唑并喹啉化合物
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
BR112013021638A2 (pt) 2011-02-25 2016-08-02 Irm Llc "compostos inibidores de trk, seu uso e composições que os compreendem"
JP5988941B2 (ja) * 2012-09-20 2016-09-07 富士フイルム株式会社 有機銅錯体、有機銅錯体溶液、銅酸化物薄膜、銅酸化物薄膜の製造方法、および、化合物
US10434132B2 (en) * 2013-06-04 2019-10-08 Academia Sinica Galactolipids-enriched plant extracts and the uses thereof
US11066412B2 (en) * 2017-11-17 2021-07-20 Academia Sinica Substituted pyrrolo[2,1-a]phthalazines and benzo[g]pyrrolo[2,1-a]phthalazines for the treatment of cancer
KR102607510B1 (ko) * 2018-10-17 2023-11-30 수벤 라이프 사이언시스 리미티드 무스카린 m1 수용체 양성 알로스테릭 조절제로서의 피롤로-피리다진 유도체
PE20220281A1 (es) 2019-03-19 2022-02-25 Boehringer Ingelheim Animal Health Usa Inc Compuestos de aza-benzotiofeno y aza-benzofurano como antihelminticos
MX2022015038A (es) 2020-05-29 2023-01-04 Boehringer Ingelheim Animal Health Usa Inc Compuestos heterociclicos como anthelminticos.
TW202333665A (zh) 2021-11-01 2023-09-01 德商百靈佳殷格翰維美迪加股份有限公司 驅蟲吡咯幷嗒𠯤化合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7891891A (en) * 1990-05-25 1991-12-31 Fujisawa Pharmaceutical Co., Ltd. Pyrrolopyridazine compounds
CA2332528A1 (fr) 1998-05-21 1999-11-25 Shionogi & Co., Ltd. Inhibiteur spla2 pyrrolo[1,2-b] pyridazine
IT1303272B1 (it) * 1998-10-29 2000-11-06 Zambon Spa Derivati triciclici inibitori della fosfodiesterasi 4
FR2792938B1 (fr) * 1999-04-28 2001-07-06 Warner Lambert Co NOUVELLES 1-AMINO TRIAZOLO [4,3-a] QUINAZOLINE-5-ONES INHIBITRICES DE PHOSPHODIESTERASES IV
DE60136530D1 (de) * 2000-03-01 2008-12-24 Janssen Pharmaceutica Nv 2,4-disubstituierte thiazolyl derivate
JPWO2002000621A1 (ja) * 2000-06-29 2004-04-22 塩野義製薬株式会社 Ｘ型ｓＰＬＡ２阻害作用を有する化合物
JP2004522713A (ja) * 2000-11-17 2004-07-29 ブリストル−マイヤーズ　スクイブ　カンパニー ｐ３８キナーゼ関連疾患の処置方法およびキナーゼインヒビターとして有用なピロロトリアジン化合物
TWI312347B (en) * 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
EP1426050A4 (fr) * 2001-08-23 2005-05-25 Takeda Pharmaceutical Inhibiteurs de jnk
US6900208B2 (en) * 2002-03-28 2005-05-31 Bristol Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
EP1581535B3 (fr) 2003-01-09 2009-09-02 Astellas Pharma Inc. Derives de pyrrolopyridazine

Also Published As

Publication number Publication date
CA2513081A1 (fr) 2004-07-29
NO20053748D0 (no) 2005-08-04
ES2291729T3 (es) 2008-03-01
PL378245A1 (pl) 2006-03-20
TW200418861A (en) 2004-10-01
NZ541232A (en) 2008-02-29
DE60317102T3 (de) 2010-02-18
US20060270678A1 (en) 2006-11-30
EP1581535A1 (fr) 2005-10-05
ATE376549T1 (de) 2007-11-15
JP4671104B2 (ja) 2011-04-13
US20050075342A1 (en) 2005-04-07
RU2005125209A (ru) 2006-01-27
DE60317102T2 (de) 2009-01-29
RU2328499C2 (ru) 2008-07-10
BR0317358A (pt) 2005-12-13
TWI332004B (en) 2010-10-21
HK1088900A1 (en) 2006-11-17
EP1581535B3 (fr) 2009-09-02
NO20053748L (no) 2005-10-07
EP1581535B1 (fr) 2007-10-24
PT1581535E (pt) 2007-12-12
IL169500A0 (en) 2007-07-04
DE60317102D1 (de) 2007-12-06
CA2513081C (fr) 2011-04-19
WO2004063197A1 (fr) 2004-07-29
MXPA05007462A (es) 2006-01-27
ES2291729T7 (es) 2010-03-31
JP2006515597A (ja) 2006-06-01
CY1107084T1 (el) 2012-10-24
EP1581535B9 (fr) 2008-03-19
US7153854B2 (en) 2006-12-26
DK1581535T3 (da) 2008-02-11
AR042833A1 (es) 2005-07-06
KR101026819B1 (ko) 2011-04-04
US7317009B2 (en) 2008-01-08
KR20050092738A (ko) 2005-09-22

Similar Documents

Publication Publication Date Title
DK1581535T5 (da) Pyrrolopyridazinderivater
ATE363383T1 (de) Schlingenware
DE602004031657D1 (de) Einführstützsystem
DE502004001683D1 (de) Kabelführung
SE0302091L (sv) Genomföring
DK1610609T3 (da) Fluid-opvarmer
AT502792A5 (de) Düsenanpressvorrichtung
DE502004011106D1 (de) 6-arylmethyl-substituierte pyrazolopyrimidine
DE502004007911D1 (de) Wischblatt
DE112004000620D2 (de) Struktoguss
NO20030424L (no) Bronnhodeplattform
ATA662003A (de) Trink-mundstück
ATE446959T1 (de) Chromenonindole
DE502004003122D1 (de) Hydrolager
DE502004002978D1 (de) N-biarylamide
FR2864125B1 (fr) Caillebotis
DE502004006563D1 (de) Brieftaubenkonstatiersystem
DE502004005162D1 (de) Leistungsregelvorricthung
DE10394329D2 (de) Mäanderstent
DE10355350A8 (de) Elektromodul
ATE406350T1 (de) Prolinylarylacetamide
DE112004002227D2 (de) Nietverarbeitungsgerät
DE10329218B4 (de) Hotflue
DE502004004175D1 (de) Verbrennungskraftmaschime
DE112004001561D2 (de) Getriebene-Antreibseinheit